Femzole 2.5

Indications:

Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women. Extended adjuvant therapy following 5 years of tamoxifen. First-line treatment for hormone-dependent advanced breast cancer. Management of advanced breast cancer in postmenopausal women previously treated with antiestrogens. Pre-operative therapy to enable breast-conserving surgery in localized hormone receptor-positive breast cancer.

Pharmacology:

Mechanism of Action: Nonsteroidal aromatase inhibitor reducing estrogen biosynthesis. Pharmacokinetics: Rapid absorption, peak levels in 1-2 hours, and a plasma half-life of about 2 days.

Dosage & Administration:

Oral: 2.5 mg once daily; continue for 5 years or until relapse. Hepatic/Renal Impairment: No dose adjustment needed; close supervision for severe impairment.

Interactions:

May interact with cimetidine and warfarin, but clinically significant reactions are rare.

Contraindications:

Hypersensitivity, pregnancy, lactation, pre-menopausal women, and severe hepatic dysfunction.

Side Effects:

Common: Hot flashes, hypercholesterolemia, fatigue, sweating, joint pain, skin rash, and gastrointestinal issues. Rare: Nervous disorders, eye disorders, and significant liver issues.

Pregnancy & Lactation:

Not recommended due to potential teratogenicity; unknown if excreted in milk.

Precautions & Warnings:

Caution in hepatic dysfunction; possible fatigue and dizziness.

Overdose Effects:

Supportive care; dialysis may be helpful.

Therapeutic Class:

Hormonal Chemotherapy

Storage Conditions:

Store below 30°C, away from light and moisture, and keep out of reach of children.